Welcome to our dedicated page for Cadrenal Therape news (Ticker: CVKD), a resource for investors and traders seeking the latest updates and insights on Cadrenal Therape stock.
Cadrenal Therapeutics develops biopharmaceutical therapies for life-threatening immune and thrombotic conditions. News about Cadrenal Therapeutics centers on CAD-1005, its investigational selective 12-lipoxygenase inhibitor for heparin-induced thrombocytopenia, including clinical-study results, FDA communications, pivotal-trial design guidance, and research involving the broader 12-LOX inhibitor platform.
Company updates also cover pipeline assets such as tecarfarin, an oral vitamin K antagonist for chronic anticoagulation settings, and frunexian, a parenteral Factor XIa inhibitor for acute hospital use. Recurring financial news includes quarterly results, cash resources, equity financings, and strategic alternatives tied to the company’s clinical development plans.
Cadrenal Therapeutics (Nasdaq: CVKD) will participate in the BIO International Convention 2026 Partnering Event, held June 22–25, 2026 in San Diego. Management plans partnering meetings focused on Phase 3‑ready CAD-1005 for Heparin-Induced Thrombocytopenia (HIT), its broader 12-LOX inhibitor platform, and late-stage oral anticoagulant tecarfarin.
CAD-1005 has completed an End-of-Phase 2 FDA meeting outlining a single pivotal Phase 3 path, following Phase 2 data suggesting reduced thrombotic events in HIT. The 12-LOX platform targets inflammatory and metabolic diseases, while tecarfarin holds FDA Orphan Drug and Fast Track designations for high-risk ESRD/AFib and LVAD-related populations.
Cadrenal Therapeutics (Nasdaq: CVKD) will participate in the virtual Lytham Partners Spring 2026 Investor Conference on May 28, 2026. The company will deliver a webcast presentation and hold one-on-one investor meetings.
The webcast is scheduled for 9:30 a.m. ET and will be available for replay.
Cadrenal Therapeutics (NASDAQ: CVKD) reported Q1 2026 results and FDA End-of-Phase 2 minutes for CAD-1005 in suspected heparin-induced thrombocytopenia (HIT). The company plans a randomized, blinded, placebo-controlled pivotal Phase 3 (~120 patients) to support a projected NDA submission in 2029. Phase 2 showed >25% absolute reduction in thrombotic events when CAD-1005 was added to standard anticoagulation. Q1 operating loss was $2.5M; cash was $2.3M as of March 31, 2026, and a $2.5M financing closed April 1, 2026.
Cadrenal Therapeutics (Nasdaq: CVKD) reported completion of an End-of-Phase 2 meeting with the FDA and received guidance to advance CAD-1005 into a pivotal Phase 3 registration trial for heparin-induced thrombocytopenia (HIT).
The planned randomized, blinded, placebo-controlled Phase 3 will enroll ~120 patients across up to 50 centers, treat patients up to 14 days on background anticoagulant therapy, use centrally adjudicated incidence of new or worsening thrombotic events in SRA-confirmed HIT as the primary endpoint, include at least one interim analysis, and targets an NDA submission in 2029. Phase 2 showed >25% absolute reduction in thrombotic events when CAD-1005 was added to standard anticoagulant therapy.
Cadrenal Therapeutics (Nasdaq: CVKD) reported Q4 and full-year results and provided an update on CAD-1005 for suspected heparin-induced thrombocytopenia (HIT). The company completed an End-of-Phase 2 FDA meeting on March 26, 2026, reported Phase 2 data showing a >25% absolute reduction in thrombotic events, and is incorporating FDA feedback into a planned Phase 3 pivotal protocol.
Cadrenal held $4.0 million cash at December 31, 2025, reported a Q4 net loss of $3.0 million, and is evaluating financing and strategic alternatives to support clinical development.
Cadrenal Therapeutics (Nasdaq: CVKD) highlighted research supporting its first-in-class 12-lipoxygenase (12-LOX) inhibitor, CAD-1005, as a potential approach to reduce obesity- and Type 2 diabetes‑related inflammation. Preclinical oral dosing showed improved glycemic control, preserved pancreatic β-cells, fewer inflammatory cells in adipose and pancreas, and lower adipose pro-inflammatory cytokines. Cadrenal acquired the 12-LOX portfolio in December 2025 and reported Phase 2 results showing reduced thrombotic events in suspected HIT. The company is developing next-generation CAD-2000.
Cadrenal Therapeutics (Nasdaq: CVKD) expanded its pipeline with a portfolio of selective 12-LOX inhibitors, including oral candidates, and reported encouraging blinded Phase 2 data for CAD-1005 in heparin-induced thrombocytopenia (HIT).
CAD-1005 showed a reduction in thrombotic events on standard anticoagulants and an End-of-Phase 2 (EOP-2) meeting is scheduled this month (March 2026). Management positions 12-LOX inhibition as a differentiated platform with potential acute and chronic applications across inflammatory and thrombotic diseases.
Cadrenal Therapeutics (Nasdaq: CVKD) reported Phase 2 results for CAD-1005 in heparin-induced thrombocytopenia (HIT) showing a >25% absolute reduction in thrombotic events versus placebo on top of standard anticoagulant therapy, despite no improvement in platelet count recovery. An End-of-Phase 2 FDA meeting is scheduled for March 2026 to align on a Phase 3 path. The trial was randomized, blinded, placebo-controlled and concluded in December 2025 after program transfer from Veralox. Detailed data will be presented at a future scientific meeting.
Cadrenal Therapeutics (NASDAQ: CVKD) highlighted the high incidence and clinical burden of thrombotic complications in heparin-induced thrombocytopenia (HIT) and promoted VLX-1005—acquired in December 2025—as the first highly selective 12-LOX inhibitor in clinical testing. Emerging Phase 2 data suggest VLX-1005 may reduce thrombotic complications in suspected HIT by targeting immune-driven platelet activation rather than only inhibiting coagulation.
VLX-1005 has Orphan Drug and Fast Track designations from the FDA and orphan status from the EMA; Cadrenal plans FDA discussions about a potential pivotal Phase 3 registration study. Cadrenal will also present at Lytham Partners on January 15, 2026.
Cadrenal Therapeutics (NASDAQ:CVKD) is positioning its pipeline as a hospital-focused anticoagulation platform on December 30, 2025. The company pairs a Phase 3-ready vitamin K antagonist, tecarfarin, aimed at renal-impaired and dialysis patients, with an acquired Factor XIa inhibitor portfolio for acute hospital care. Cadrenal also holds VLX-1005, a Phase 2 12-LOX inhibitor with Orphan Drug and Fast Track designations for heparin-induced thrombocytopenia (HIT). Together the assets span chronic, acute, and immune-mediated anticoagulation failures, targeting high-acuity hospital needs rather than broad-market incremental gains.